CAS |
No.127869-51-6 |
英文名称 |
C-Type Natriuretic Peptide (CNP) (1-22), human |
分子式 |
C93H157N27O28S3 |
分子量 |
2197.6 |
溶解性 |
Soluble in Water ≥5mg/mL |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:-20℃,1 year;Insolvent(母液):-20℃,6 months;-80℃,1 year |
靶点 |
NPR-B |
通路 |
Others |
背景说明 |
是 CNP 的 1-22 片段,是一种利钠肽受体 B (NPR-B) 激动剂。 |
生物活性 |
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.[1-3] |
In Vitro |
C-Type Natriuretic Peptide (CNP) (1-22), human (0.01, 0.1, 1,10, 100, 1000 nM) 以浓度依赖的方式增加表达人 NPR-B 的 CHO 细胞中 cGMP 产量[1]。 |
In Vivo |
单次静脉注射 C-Type Natriuretic Peptide (CNP) (1-22), human 后 CNP 免疫反应性的 PK 参数[1]:Dose(nM/kg)AUC0-∞(pM·min/mL)MRT0-∞(min)T1/2(min)CLtot(mL/min/kg)Vdss(mL/kg) 20320±541.02±0.181.42±0.4563.9±11.964.2±5.1单次皮下给药 C-Type Natriuretic Peptide (CNP) (1-22), human 后 CNP 免疫反应性的 PK 参数[1]:Dose(nM/kg)Cmax(pM/mL)Tmax(min)AUC0-∞(pM·min/mL)MRT0-∞(min)T1/2(min)BA(%)509.02±3.745.0±0.0152±7313.9±3.410.0±5.019±9Each value represents the mean±SD of 3 rats. MRT=mean residence time, CLtot=total clearance, T1/2=half-life period, BA=bioavailability.C-Type Natriuretic Peptide (CNP) (1-22), human 以 2 nM 的剂量在应用 24 和 48 小时后,可诱导微毒素引起的惊厥的严重程度增加[3]。 |
动物实验 |
Rats[3]Rats are preliminarily kindled with picrotoxin and convulsion is monitored. Rats then receive I.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) (0.2, 1 or 2 nM in 2 mcl of 0.9% NaCI) under conditions of free behavior. Control animals receive an equal volume of saline. Within 10 min after the injections of the peptides, picrotoxin (1.5 mg/kg) is administered i.p. and the convulsion severity is evaluated as mentioned above[3]. |
数据来源文献 |
[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [2]. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [3]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. |
规格 |
1mg |
单位 |
瓶 |